Enanta Pharmaceutica (ENTA)

$6.56 -0.42 (-6.02%)
Market Cap 140.23M
Revenue (ttm) 67.64M
Net Income (ttm) -116.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -171.57%
Debt to Equity Ratio 0.00
Volume 189,400
Avg Vol 154,382
Day's Range N/A - N/A
Shares Out 21.38M
Stochastic %K 3%
Beta 0.84
Analysts Strong Sell
Price Target $17.00

Company Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 607 0800
Fax: 617 607 0530
Address:
4 Kingsbury Avenue, Watertown, United States
working_girl
working_girl Jul. 9 at 4:55 PM
$ENTA No news. Why is this POS cratering today?
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 10:30 AM
JMP Securities updates rating for Enanta Pharma ( $ENTA ) to Market Outperform, target set at 21 → 23.
0 · Reply
justiceforb_85
justiceforb_85 Jul. 6 at 11:30 PM
$ENTA will be a leader in the RSV anti-viral space.
0 · Reply
Estimize
Estimize Jun. 25 at 7:05 PM
Wall St is expecting -0.84 EPS for $ENTA Q3 [Reporting 08/11 AMC] http://www.estimize.com/intro/enta?chart=historical&metric_name=eps&utm_c
0 · Reply
FullportFox
FullportFox Jun. 15 at 6:21 PM
$ENTA news was good
1 · Reply
Jennx6
Jennx6 Jun. 12 at 3:57 PM
$ENTA Status for P2b trial in RSV was updated earlier this month to show they're no longer recruiting. Statisticians are doing their thing. Results are coming in the short-term.
0 · Reply
Pk201Twits
Pk201Twits Jun. 11 at 5:31 PM
$ENTA check $NUVB
1 · Reply
mattmerc512
mattmerc512 Jun. 11 at 5:28 PM
$ENTA oof I bought high
0 · Reply
AceSP
AceSP Jun. 11 at 5:24 PM
$ENTA so I guess the news on this was basically worthless?
0 · Reply
Raj_mach9
Raj_mach9 Jun. 11 at 5:02 PM
$ENTA this needs to be trending on ST for any price action
0 · Reply
Latest News on ENTA
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

Jun 11, 2025, 12:34 PM EDT - 4 weeks ago

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 27, 2025, 7:00 AM EDT - 6 weeks ago

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

May 22, 2025, 7:00 AM EDT - 7 weeks ago

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

May 12, 2025, 4:01 PM EDT - 2 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Apr 8, 2025, 7:00 AM EDT - 3 months ago

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 17, 2025, 7:00 AM EDT - 4 months ago

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Mar 12, 2025, 7:00 AM EDT - 4 months ago

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Feb 10, 2025, 4:01 PM EST - 5 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 7:00 AM EST - 6 months ago

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Dec 24, 2024, 7:00 AM EST - 7 months ago

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Dec 9, 2024, 6:30 AM EST - 7 months ago

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Dec 6, 2024, 5:00 PM EST - 7 months ago

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Nov 25, 2024, 4:01 PM EST - 8 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Sep 26, 2024, 6:00 AM EDT - 10 months ago

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Sep 3, 2024, 7:00 AM EDT - 11 months ago

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

May 7, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

May 6, 2024, 8:34 PM EDT - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

May 6, 2024, 4:01 PM EDT - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2024, 7:10 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Apr 17, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Mar 6, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Feb 7, 2024, 10:04 PM EST - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Feb 7, 2024, 4:01 PM EST - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Jan 31, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta: Multiple Shots On Goal For RSV Makes This A Must Watch

Nov 30, 2023, 3:34 PM EST - 1 year ago

Enanta: Multiple Shots On Goal For RSV Makes This A Must Watch

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Nov 22, 2023, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call Transcript

Nov 20, 2023, 9:43 PM EST - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q4 2023 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Nov 20, 2023, 4:01 PM EST - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Nov 13, 2023, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Oct 13, 2023, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

Sep 17, 2023, 12:00 PM EDT - 1 year ago

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023

Sep 7, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript

Aug 7, 2023, 8:42 PM EDT - 2 years ago

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Aug 7, 2023, 4:01 PM EDT - 2 years ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

Jun 20, 2023, 8:06 AM EDT - 2 years ago

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Jun 20, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023

Jun 7, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023

Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference

May 31, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference

Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

May 9, 2023, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2023 Earnings Call Transcript

May 8, 2023, 6:48 PM EDT - 2 years ago

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2023 Earnings Call Transcript

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

May 8, 2023, 4:01 PM EDT - 2 years ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET

Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

May 8, 2023, 4:01 PM EDT - 2 years ago

Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

working_girl
working_girl Jul. 9 at 4:55 PM
$ENTA No news. Why is this POS cratering today?
0 · Reply
JarvisFlow
JarvisFlow Jul. 7 at 10:30 AM
JMP Securities updates rating for Enanta Pharma ( $ENTA ) to Market Outperform, target set at 21 → 23.
0 · Reply
justiceforb_85
justiceforb_85 Jul. 6 at 11:30 PM
$ENTA will be a leader in the RSV anti-viral space.
0 · Reply
Estimize
Estimize Jun. 25 at 7:05 PM
Wall St is expecting -0.84 EPS for $ENTA Q3 [Reporting 08/11 AMC] http://www.estimize.com/intro/enta?chart=historical&metric_name=eps&utm_c
0 · Reply
FullportFox
FullportFox Jun. 15 at 6:21 PM
$ENTA news was good
1 · Reply
Jennx6
Jennx6 Jun. 12 at 3:57 PM
$ENTA Status for P2b trial in RSV was updated earlier this month to show they're no longer recruiting. Statisticians are doing their thing. Results are coming in the short-term.
0 · Reply
Pk201Twits
Pk201Twits Jun. 11 at 5:31 PM
$ENTA check $NUVB
1 · Reply
mattmerc512
mattmerc512 Jun. 11 at 5:28 PM
$ENTA oof I bought high
0 · Reply
AceSP
AceSP Jun. 11 at 5:24 PM
$ENTA so I guess the news on this was basically worthless?
0 · Reply
Raj_mach9
Raj_mach9 Jun. 11 at 5:02 PM
$ENTA this needs to be trending on ST for any price action
0 · Reply
topstockalerts
topstockalerts Jun. 11 at 4:55 PM
$ENTA not a bad place for a swing idea 💡💡
0 · Reply
Raj_mach9
Raj_mach9 Jun. 11 at 4:54 PM
$ENTA why is it not moving even after a FdA approval
1 · Reply
Bolo1218
Bolo1218 Jun. 11 at 4:50 PM
$ENTA
0 · Reply
aperzy20
aperzy20 Jun. 11 at 4:47 PM
$ENTA FDA APPROVAL!! LFGG $JEM $HSDT https://www.benzinga.com/pressreleases/25/06/b45889201/enanta-pharmaceuticals-partner-abbvie-receives-u-s-fda-approval-of-an-expanded-indication-for-mavy
0 · Reply
aperzy20
aperzy20 Jun. 11 at 4:45 PM
$ENTA big news LETS GOOO
0 · Reply
aperzy20
aperzy20 Jun. 11 at 4:45 PM
$ENTA
0 · Reply
Tarde75
Tarde75 Jun. 11 at 4:42 PM
$ENTA
0 · Reply
PenkeTrading
PenkeTrading Jun. 4 at 10:48 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Enanta Pharmaceuticals Inc. Is that bullish or bearish? $ENTA #Enanta #RsiOverbought #NASDAQ
1 · Reply
DARKP00L
DARKP00L Jun. 3 at 2:56 PM
$ENTA 10:47 on Jun. 03 2025 Enanta Pharmaceuticals shares are trading higher after JMP Securities maintained an Outperform rating on the stock and raised its price target from $23 to $24. #tradeideas
0 · Reply
Rider_on_the_Stonk
Rider_on_the_Stonk Jun. 3 at 1:59 PM
$ENTA great SP movement. Horrible volume
0 · Reply
working_girl
working_girl May. 27 at 6:17 PM
$ENTA WTF everything else higher except this POS
0 · Reply